Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review

Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review

Bladder cancer is the ninth most common cancer worldwide. Over 75% of non-muscle invasive cancer patients require conservative local treatment, while the remaining 25% of patients undergo radical cystectomy or radiotherapy. Immune checkpoint inhibitors represent a novel class of immunotherapy drugs...

Full description

Bibliographic Details
Main Authors: Biagio Barone, Armando Calogero, Luca Scafuri, Matteo Ferro, Giuseppe Lucarelli, Erika Di Zazzo, Enrico Sicignano, Alfonso Falcone, Lorenzo Romano, Luigi De Luca, Francesco Oliva, Benito Fabio Mirto, Federico Capone, Ciro Imbimbo, Felice Crocetto
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
muscle-invasive bladder cancer
adjuvant
neoadjuvant
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/10/2545

Internet

https://www.mdpi.com/2072-6694/14/10/2545

Similar Items